Skip to main content

Catalyst Calendar

Mon, Aug 10, 2026

1 updates

9:01 AM

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

2seventybio.com

Thu, Jul 30, 2026

1 updates

6:59 AM

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

2seventybio.com

Mon, Jul 20, 2026

1 updates

6:59 AM

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

2seventybio.com

Mon, Jul 13, 2026

1 updates

6:59 AM

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

2seventybio.com

Thu, Jun 18, 2026

1 updates

6:59 AM

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

2seventybio.com

Wed, Jun 17, 2026

1 updates

4:16 PM

Bristol Myers Squibb Announces Dividend

2seventybio.com

Mon, Jun 8, 2026

1 updates

6:59 AM

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

2seventybio.com

Tue, Jun 2, 2026

1 updates

8:00 AM

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

2seventybio.com

Mon, Jun 1, 2026

2 updates

6:59 AM

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

2seventybio.com

6:55 AM

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

2seventybio.com

Sat, May 30, 2026

1 updates

2:15 PM

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Trial Results • Phase 22seventybio.com

Fri, May 29, 2026

1 updates

8:00 AM

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

Trial Results • Phase 32seventybio.com

Wed, May 27, 2026

1 updates

6:59 AM

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

2seventybio.com

Thu, May 21, 2026

1 updates

5:01 PM

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

2seventybio.com

Wed, May 20, 2026

1 updates

6:59 AM

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

2seventybio.com